This podcast discusses a new preventative medicine called nirsevimab (Beyfortus), which is now available to protect infants and high-risk toddlers from respiratory syncytial virus (RSV). …

This short video summarizes new research findings on nirsevimab and how it can prevent RSV in late preterm and term infants. The trial included 1490 …

This 3-minute video discusses the use of nirsevimab (Beyfortus™) to protect vulnerable infants from RSV. Dr. Paul Offit explains its benefits, clinical trial results, and …

This webpage provides guidance and resources on respiratory syncytial virus (RSV) and immunization. RSV is a common lung virus that mainly affects young children under …

This announcement explains that providers can order nirsevimab (Beyfortus) through Vaccines for Children (VFC). It covers the following areas of consideration: dosage and administration, eligible …

This webpage explains how to order Beyfortus, a monoclonal antibody that may prevent young infants from getting respiratory syncytial virus (RSV). It covers discounts, reimbursements, …

This webinar provides guidance on ordering and administering nirsevimab, a monoclonal antibody for preventing severe RSV in infants. Presenters represent the Washington Chapter of the …

This statement describes a shortage of nirsevimab and provides further recommendations. ACOG and SMFM recommend Pfizer’s RSVpreF vaccine for pregnant women as an alternative. Pediatricians …

This webpage features responses to 10 frequently asked questions (FAQs) that parents ask about RSV and nirsevimab. It also addresses proper hand hygiene. Nirsevimab, along …

This memo outlines recommendations and an implementation plan for nirsevimab (Beyfortus™), a long-acting monoclonal antibody effective against respiratory syncytial virus (RSV), at Lucile Packard Children’s …